TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE PARASITOLOGY IDENTIFICATION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 EUROPE PARASITOLOGY IDENTIFICATION MARKET: GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 DBMR VENDOR SHARE ANALYSIS
2.9 MULTIVARIATE MODELING
2.10 PRODUCTS LIFELINE CURVE
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING CASES OF CHRONIC AND INFECTIOUS PARASITIC INFECTIONS
3.1.2 TECHNOLOGIAL ADVANCEMENTS IN THE IDENTIFICATION TECHNIQUES
3.1.3 INCREASING R&D EXPENDITURE
3.1.4 GROWING GOVERNMENT INITIATIVES
3.2 RESTRAINTS
3.2.1 HIGH COST OF DEVICES
3.2.2 STRINGENT REGULATIONS
3.3 OPPORTUNITIES
3.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
3.3.2 IMPROVING BETTER HEALTH OUTCOMES IN EMERGING COUNTRIES
3.4 CHALLENGE
3.4.1 ADOPTION OF NEW TECHNOLOGIES IN THE DEVELOPING COUNTRIES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EUROPE PARASITOLOGY IDENTIFICATION MARKET, BY PRODUCTS
6.1 OVERVIEW
6.2 DEVICES
6.2.1 FLOW CYTOMETERS
6.2.2 MICROARRAYS
6.2.3 PCR
6.2.4 ELISA
6.2.5 MASS SPECTROMETERS
6.2.6 POLYSTAINERS
6.2.7 HIGH-POWER MICROSCOPES
6.2.8 AUTOMATED MICROBIAL IDENTIFICATION SYSTEMS
6.2.9 OTHERS
6.3 CONSUMABLES AND ACCESSORIES
6.3.1 PLATES& MEDIA
6.3.2 REAGENTS & KITS
6.3.3 OTHERS
7 EUROPE PARASITOLOGY IDENTIFICATION MARKET, BY METHODS
7.1 OVERVIEW
7.2 FECAL IDENTIFICATION
7.3 MORPHOLOGICAL IDENTIFICATION
7.4 MOLECULAR TECHNIQUES
7.5 MALDI-TOF MS
7.6 IMMUNOLOGICAL TECHNIQUES
7.6.1 HAEMAGGLUTINATION ASSAY
7.6.2 ELISA
7.6.3 OTHERS
7.7 RAPID DIAGNOSTIC TESTS (RDTS)
7.8 OTHERS
8 EUROPE PARASITOLOGY IDENTIFICATION MARKET, BY PATHOGEN TYPE
8.1 OVERVIEW
8.2 PROTOZOAN
8.3 HELMINTHS
8.4 ECTOPARASITES
?
9 EUROPE PARASITOLOGY IDENTIFICATION MARKET, BY SAMPLE
9.1 OVERVIEW
9.2 FECES
9.3 BLOOD
9.4 URINE
9.5 OTHERS
10 EUROPE STOOL CONCENTRATION AND SAMPLE PREPARATION FOR PARASITOLOGY IDENTIFICATION MARKET, BY PRODUCTS
10.1 OVERVIEW
10.2 CONCENTRATION TECHNIQUE
10.2.1 FLOTATION TECHNIQUES
10.2.1.1 BRINE FLOTATION
10.2.1.2 SUGAR FLOTATION
10.2.1.3 ZINC-SULFATE FLOTATION
10.2.1.4 OTHERS
10.2.2 SEDIMENTATION TECHNIQUES
10.2.2.1 SIMPLE SEDIMENTATION
10.2.2.2 CENTRIFUGAL SEDIMENTATION
10.2.2.3 FORMAL-ETHYL ACETATE SEDIMENTATION/ DIPHASIC SEDIMENTATION TECHNIQUE
10.2.2.4 FILTRATION COMBINED WITH CENTRIFUGATION
10.2.2.5 DIRECT WET MOUNT
10.2.2.6 OTHERS
10.3 UNCONCENTRATION TECHNIQUE
11 EUROPE PARASITOLOGY IDENTIFICATION MARKET, BY END USER
11.1 OVERVIEW
11.2 DIAGNOSTIC CENTERS
11.3 HOSPITALS
11.4 CLINICS
11.5 OTHERS
12 EUROPE PARASITOLOGY IDENTIFICATION MARKET, BY GEOGRAPHY
12.1 EUROPE
12.1.1 GERMANY
12.1.2 ITALY
12.1.3 U.K.
12.1.4 FRANCE
12.1.5 SPAIN
12.1.6 NETHERLANDS
12.1.7 BELGIUM
12.1.8 SWITZERLAND
12.1.9 TURKEY
12.1.10 RUSSIA
12.1.11 REST OF EUROPE
13 EUROPE PARASITOLOGY IDENTIFICATION CONTROL MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT ANALYSIS
14.1 STRENGTH
14.2 WEAKNESS
14.3 OPPORTUNITY
14.4 THREAT
14.5 DATA BRIDGE MARKET RESEARCH ANALYSIS
15 COMPANY PROFILE
15.1 ABBOTT
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 REVENUE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 THERMO FISHER SCIENTIFIC INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENTS
15.3 SHIMADZU CORPORATION
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPEMNT
?
15.4 BRUKER
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 BD
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.6 BIOMeRIEUX SA
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 COMPANY SHARE ANALYSIS
15.6.4 PRODUCT PORTFOLIO
15.6.5 RECENT DEVELOPMENTS
15.7 ALTONA DIAGNOSTICS GMBH
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 BIOMERICA, INC.
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BIO-RAD LABORATORIES, INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.10 CREATIVE DIAGNOSTICS
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.11 EUROFINS SCIENTIFIC
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 SERVICE PORTFOLIO
15.11.4 RECENT DEVELOPMENTS
15.12 LIFERIVER BIO-TECH (UNITED STATES) CORP.
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 LUMINEX CORPORATION
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 MERIDIAN BIOSCIENCE INC.
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS:
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.15 ORGENTEC DIAGNOSTIKA GMBH
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENTS
15.16 R-BIOPHARM AG
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT CATEGORY
15.16.3 RECENT DEVELOPMENT
15.17 QUEST DIAGNOSTICS INCORPORATED
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 TECAN TRADING AG
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENTS
15.19 TRINITY BIOTECH
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
?
15.20 VIRION/SERION
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.21 VWR INTERNATIONAL, LLC (PART OF AVANTOR)
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 CONCLUSION
18 RELATED REPORTS